Literature DB >> 21546970

Window of opportunity for daclizumab.

Kimberly S Schluns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21546970     DOI： 10.1038/nm0511-545

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

3.  An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.

Authors:  Jayne F Martin; Justin S A Perry; Neha R Jakhete; Xiang Wang; Bibiana Bielekova
Journal:  J Immunol       Date:  2010-06-11       Impact factor: 5.422

4.  Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.

Authors:  F Granucci; C Vizzardelli; N Pavelka; S Feau; M Persico; E Virzi; M Rescigno; G Moro; P Ricciardi-Castagnoli
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

5.  Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells.

Authors:  Florian W Velten; Florian Rambow; P Metharom; Sergij Goerdt
Journal:  Mol Immunol       Date:  2006-10-04       Impact factor: 4.407

Review 6.  Daclizumab.

Authors:  Marcus Mottershead; James Neuberger
Journal:  Expert Opin Biol Ther       Date:  2007-10       Impact factor: 4.388

7.  A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.

Authors:  Simone C Wuest; Jehad H Edwan; Jayne F Martin; Sungpil Han; Justin S A Perry; Casandra M Cartagena; Eiji Matsuura; Dragan Maric; Thomas A Waldmann; Bibiana Bielekova
Journal:  Nat Med       Date:  2011-05-01       Impact factor: 53.440

8.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307
  9 in total
  7 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

2.  CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Authors:  Andrew J Rech; Rosemarie Mick; Sunil Martin; Adri Recio; Nicole A Aqui; Daniel J Powell; Theresa A Colligon; Jennifer A Trosko; Leah I Leinbach; Charles H Pletcher; Carol K Tweed; Angela DeMichele; Kevin R Fox; Susan M Domchek; James L Riley; Robert H Vonderheide
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

Review 3.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 4.  Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.

Authors:  Laura E Baldassari; John W Rose
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Authors:  Heinz Wiendl; Catharina C Gross
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

Review 6.  Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.

Authors:  Zhong-Xiang Xie; Hong-Liang Zhang; Xiu-Juan Wu; Jie Zhu; Di-Hui Ma; Tao Jin
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

7.  Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster.

Authors:  Miju Kim; Tae-Jin Kim; Hye Mi Kim; Junsang Doh; Kyung-Mi Lee
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.